ABSTRACT
AIMS: The implementation of the 2013 European Society of Cardiology (ESC) Core Curriculum guidelines for acute cardiovascular care (acc) training among European countries is unknown. We aimed to evaluate the current status of acc training among cardiology trainees and young cardiologists (<40 years) from ESC countries. METHODS AND RESULTS: The survey (March-July 2019) asked about details of cardiology training, self-confidence in acc technical and non-technical skills, access to training opportunities, and needs for further training in the field. Overall 614 young doctors, 31 (26-43) years old, 55% males were surveyed. Place and duration of acc training differed between countries and between centres in the same country. Although the majority of the respondents (91%) had completed their acc training, the average self-confidence to perform invasive procedures and to manage acc clinical scenarios was low-44% (27.3-70.4). The opportunities for simulation-based learning were scarce-18% (5.8-51.3), as it was previous leadership training (32%) and knowledge about key teamwork principles was poor (48%). The need for further acc training was high-81% (61.9-94.3). Male gender, higher level of training centres, professional qualifications of respondents, longer duration of acc/intensive care training, debriefings, and previous leadership training as well as knowledge about teamwork were related to higher self-confidence in all investigated aspects. CONCLUSIONS: The current cardiology training program is burdened by deficits in acc technical/non-technical skills, substantial variability in programs across ESC countries, and a clear gender-related disparity in outcomes. The forthcoming ESC Core Curriculum for General Cardiology is expected to address these deficiencies.
Subject(s)
Cardiologists , Cardiology , Adult , Critical Care , Europe , Female , Humans , Male , Surveys and QuestionnairesABSTRACT
BACKGROUND: COVID-19 has challenged the health system organization requiring a fast reorganization of diagnostic/therapeutic pathways for patients affected by time-dependent diseases such as acute coronary syndromes (ACS). AIM: To describe ACS hospitalizations, management, and complication rate before and after the COVID-19 pandemic was declared. DESIGN: Ecological retrospective study. Methods: We analyzed aggregated epidemiological data of all patients > 18 years old admitted for ACS in twenty-nine hub cardiac centers from 17 Countries across 4 continents, from December 1st, 2019 to April 15th, 2020. Data from December 2018 to April 2019 were used as historical period. RESULTS: A significant overall trend for reduction in the weekly number of ACS hospitalizations was observed (20.2%; 95% confidence interval CI [1.6, 35.4] P = 0.04). The incidence rate reached a 54% reduction during the second week of April (incidence rate ratio: 0.46, 95% CI [0.36, 0.58]) and was also significant when compared to the same months in 2019 (March and April, respectively IRR: 0.56, 95%CI [0.48, 0.67]; IRR: 0.43, 95%CI [0.32, 0.58] p < 0.001). A significant increase in door-to-balloon, door-to-needle, and total ischemic time (p <0.04 for all) in STEMI patents were reported during pandemic period. Finally, the proportion of patients with mechanical complications was higher (1.98% vs. 0.98%; P = 0.006) whereas GRACE risk score was not different. CONCLUSIONS: Our results confirm that COVID-19 pandemic was associated with a significant decrease in ACS hospitalizations rate, an increase in total ischemic time and a higher rate of mechanical complications on a international scale.
Subject(s)
Acute Coronary Syndrome , COVID-19 , Acute Coronary Syndrome/epidemiology , Acute Coronary Syndrome/therapy , Adolescent , Hospitalization , Humans , Pandemics , Retrospective Studies , SARS-CoV-2ABSTRACT
BACKGROUND: The present survey aims to describe the intensive cardiac care unit organization and admission policies in Europe. METHODS: A total of 228 hospitals (61% academic) from 27 countries participated in this survey. In addition to the organizational aspects of the intensive cardiac care units, including classification of the intensive cardiac care unit levels, data on the admission diagnoses were gathered from consecutive patients who were admitted during a two-day period. Admission policies were evaluated by comparing illness severity with the intensive cardiac care unit level. Gross national income was used to differentiate high-income countries (n=13) from middle-income countries (n=14). RESULTS: A total of 98% of the hospitals had an intensive cardiac care unit: 70% had a level 1 intensive cardiac care unit, 76% had a level 2 intensive cardiac care unit, 51% had a level 3 intensive cardiac care unit, and 60% of the hospitals had more than one intensive cardiac care unit level. High-income countries tended to have more level 3 intensive cardiac care units than middle-income countries (55% versus 41%, p=0.07). A total of 5159 admissions were scored on illness severity: 63% were low severity, 24% were intermediate severity, and 12% were high severity. Patients with low illness severity were predominantly admitted to level 1 intensive cardiac care units, whereas patients with high illness severity were predominantly admitted to level 2 and 3 intensive cardiac care units. A policy mismatch was observed in 12% of the patients; some patients with high illness severity were admitted to level 1 intensive cardiac care units, which occurred more often in middle-income countries, whereas some patients with low illness severity were admitted to level 3 intensive cardiac care units, which occurred more frequently in high-income countries. CONCLUSION: More than one-third of the admitted patients were considered intermediate or high risk. Although patients with higher illness severity were mostly admitted to high-level intensive cardiac care units, an admission policy mismatch was observed in 12% of the patients; this mismatch was partly related to insufficient logistic intensive cardiac care unit capacity.
Subject(s)
Heart Diseases/therapy , Intensive Care Units/organization & administration , Patient Admission/statistics & numerical data , Europe/epidemiology , Heart Diseases/epidemiology , Humans , Morbidity/trends , Risk Factors , Surveys and QuestionnairesABSTRACT
BACKGROUND: Cardiogenic shock (CS) is the leading cause of death in patients admitted for acute myocardial infarction (MI). Despite the recent advances in reperfusion and medical treatment mortality remains unacceptably high. Whether cells of the blood compartment in CS-patients are activated and release microparticles (cMPs) that may be both messengers and biomarkers of cell damage is not known. We aimed to investigate the cMP subtypes and parental activated cells of ST-elevation MI (STEMI)-patients complicated by CS and that of non-CS STEMI-patients (non-CS) in order to identify a cMP signature that could aid CS patient's risk stratification. METHODS: Clinically-characterized STEMI-patients with and without CS (36/group) were included. Treatment was delivered according to guidelines and included primary percutaneous coronary intervention. cMPs were characterized by triple-labeling flow cytometry using Annexin V and cell surface-specific monoclonal antibodies. RESULTS: Increased levels of leukocyte-derived (neutrophil and granulocyte origin) and platelet-derived cMPs were detected in CS compared to non-CS patients. A signature of cMPs derived from platelets, leukocytes, and endothelium discriminated CS-patients (AUC of 0.743±0.059 [95% CI: 0.628-0.859], P<0.0001) and predicted mortality in CS (AUC of 0.869±0.06 [95% CI: 0.750-0.988], P<0.0001). In CS-patients, a higher number of platelet- and monocyte-cMPs and of tissue factor-rich cMPs associated to worse myocardial blush grade and thrombolysis in myocardial infarction flow. CONCLUSIONS: cMPs derived from proinflammatory and prothrombotic cells were found to be elevated in CS-patients. In treated as per guidelines CS patients, granulocytes and neutrophils remained activated and actively shed cMPs. These cMPs were biomarkers of adverse prognosis in CS. TRANSLATIONAL ASPECT: Increased levels of leukocyte and platelet-derived circulating microparticles (cMPs) are found in cardiogenic shock (CS) patients as compared to non-CS patients. In CS-patients, a higher number of platelet- and monocyte-cMPs and a higher number of tissue factor-rich cMPs were associated to worse myocardial reperfusion. A specific prothrombotic and proinflammatory cMPs signature in cardiogenic shock (CS) patients is a potential discriminator and survival prognostic biomarker for CS, which could aid management and improve clinical outcomes.
Subject(s)
Cell-Derived Microparticles/metabolism , ST Elevation Myocardial Infarction/blood , ST Elevation Myocardial Infarction/epidemiology , Severity of Illness Index , Shock, Cardiogenic/blood , Shock, Cardiogenic/epidemiology , Aged , Biomarkers/blood , Cohort Studies , Female , Humans , Male , Middle Aged , Prospective Studies , Retrospective Studies , ST Elevation Myocardial Infarction/diagnosis , Shock, Cardiogenic/diagnosisABSTRACT
Primary graft dysfunction after heart transplantation (HTx) has a very high mortality rate, especially if the left ventricle (PGD-LV) is involved. Early diagnosis is important to select the appropriate therapy to improve prognosis. The value of high-sensitivity troponin T (HS-TNT) measurement obtained at patient arrival at the intensive care unit was analyzed in 71 HTx patients. Mild or moderate PGD-LV was defined by hemodynamic compromise with one of the following criteria: left ventricular ejection fraction <40%, hemodynamic compromise with right atrial pressure >15 mm Hg, pulmonary capillary wedge pressure >20 mm Hg, cardiac index <2.0 L/min/m2, hypotension (mean arterial pressure <70 mm Hg), and need for high-dose inotropes (inotrope score >10) or newly placed intra-aortic balloon pump. The mean recipient age was 54 ± 12 years (73% men), and donor age was 47 ± 11 years. Ischemic time was 200 ± 51 minutes, and coronary bypass time was 122 ± 31 minutes. Nine (13%) HTx patients were diagnosed with PGD-LV post-HTx, 8 with biventricular dysfunction. Four patients died, 2 with PGD-LV (22%) and 2 without PGD (4%). Mean HS-TNT before HTx was 158 ± 565 ng/L, and post-HT was 1621 ± 1269 ng/L. The area under the curve (receiver-operator characteristic) of HS-TNT to detect patients at risk of PGD-LV was 0.860 (P < .003). A cutoff value of HS-TNT >2000 ng/L had a sensitivity of 75% and specificity of 87% to identify patients at risk of PGD-LV. Multivariate analysis identified HS-TNT >2000 ng/L (P < .02) and coronary bypass-time (P < .01) as independent predictors of PGD-LV. HS-TNT >2000 ng/L at intensive care admission after HT and prolonged coronary bypass time were the most powerful predictors of PGD-LV. HS-TNT may be helpful for early detection of HTx patients at risk of PGD-LV.
Subject(s)
Heart Transplantation/adverse effects , Primary Graft Dysfunction/diagnosis , Troponin T/metabolism , Ventricular Dysfunction, Left/diagnosis , Biomarkers/metabolism , Coronary Artery Bypass/adverse effects , Early Diagnosis , Female , Heart Ventricles , Humans , Male , Middle Aged , Postoperative Complications/diagnosis , Prognosis , ROC Curve , Sensitivity and Specificity , Stroke Volume/physiology , Ventricular Dysfunction, Left/etiologySubject(s)
Algorithms , Cardiac Resynchronization Therapy , Cardiovascular Agents/therapeutic use , Death, Sudden, Cardiac/prevention & control , Defibrillators, Implantable , Extracorporeal Membrane Oxygenation , Heart Failure/therapy , Practice Guidelines as Topic , Acute Disease , Adrenergic beta-Antagonists/therapeutic use , Aminobutyrates/therapeutic use , Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Benzazepines/therapeutic use , Biphenyl Compounds , Chronic Disease , Drug Combinations , Early Medical Intervention , Echocardiography , Europe , Heart Failure/blood , Heart Failure/diagnosis , Humans , Ivabradine , Mineralocorticoid Receptor Antagonists/therapeutic use , Natriuretic Peptides/blood , Spain , Stroke Volume , Tetrazoles/therapeutic use , ValsartanABSTRACT
BACKGROUND: Circulating microparticle (cMP) levels are increased in the acute phase of ST-elevation myocardial infarction (STEMI) and associate with microvascular obstruction; however, the precise cMP-parental cell signature and activation level are not elucidated. Here, we aimed to study the cMP signature in STEMI-patients and whether cMP phenotype changes in relation to onset of pain-to-PCI [ischemic time (IT)]-elapsed time. METHODS: Blood was taken at PCI from the culprit coronary and the peripheral circulation in STEMI-patients (N=40). Two control groups were included: peripheral blood of age-matched patients recovering from STEMI [after 72 h] and of control individuals (N=20/group). cMP-parental origin and activation level were characterized by triple-labeling flow cytometry. RESULTS: Procoagulant annexin V-positive cMPs bearing parental cell markers as well as markers of activated cells displayed a significantly different profile in STEMI-patients, in control individuals and in patients recovering from STEMI. cMPs derived from monocytes, endothelium, and activated vascular cells were higher in the culprit coronary artery than in peripheral blood in STEMI-patients, especially in patients intervened at short IT. Indeed, cMP levels in coronary blood were inversely related to IT duration (more abundant in thrombi with pain-to-PCI time<180 min). CONCLUSIONS: A characteristic [CD66b+/CD62E+/CD142+] cMP signature in the systemic circulation reflects the formation of coronary thrombotic occlusions in STEMI-patients. Changes in the cMP signature in the culprit coronary artery blood reveal the sensitivity of MPs to detect the ischemia-elapsed time. Interestingly, cMPs in peripheral blood may be sensitive markers of the thrombo-occlusive vascular process developing in the coronary arteries of STEMI-patients.
Subject(s)
Cell-Derived Microparticles/metabolism , Coronary Occlusion/blood , Myocardial Infarction/blood , Pain/metabolism , Aged , Angioplasty, Balloon, Coronary/methods , Biomarkers/blood , Biomarkers/metabolism , Coronary Occlusion/metabolism , Coronary Vessels/metabolism , Electrocardiography , Female , Flow Cytometry/methods , Humans , Male , Middle Aged , Myocardial Infarction/metabolism , Myocardial Infarction/surgery , Myocardial Revascularization/methods , Pain/diagnosis , Pain/surgery , Percutaneous Coronary Intervention/methods , Phenotype , Predictive Value of Tests , Severity of Illness Index , Thrombectomy/methods , Thrombosis/metabolismABSTRACT
BACKGROUND: The clinical profile of heart transplantation (HT) recipients has changed in recent years. Nowadays, we have to deal with a higher number of co-morbidities, including peripheral vascular disease (PVD). Previous studies suggest an increase in post-HT morbidity and mortality associated with PVD, especially when it is symptomatic. Our study aims were to analyze the prognostic implications of the presence of PVD before transplantation and to determine the factors associated with its development after it. METHODS: HT patients (n = 217) who survived the first year after surgery were included in the study. Mean follow-up was 9 ± 5 years. RESULTS: There were no statistically significant differences in mortality rates between patients with PVD (before or after HT) and those without. One third of patients with PVD required surgery in the post-HT monitoring, either revascularization or amputation. Furthermore, the prevalence of PVD was doubled. Dyslipidemia before HT (odds ratio [OR]: 2.9, 95% confidence interval [CI]: 1.3-6.4; P < .01) and older recipient age (OR: 1.05, 95% CI: 1.01-1.09; P < .05) were independently associated with development of PVD by means of multivariate analysis. CONCLUSIONS: The presence of PVD must be evaluated individually in candidates for heart transplantation despite being a relative contraindication to it at the present time.
Subject(s)
Aortic Aneurysm/epidemiology , Aortic Diseases/epidemiology , Carotid Stenosis/epidemiology , Cerebrovascular Disorders/epidemiology , Dyslipidemias/epidemiology , Heart Failure/surgery , Heart Transplantation , Peripheral Vascular Diseases/epidemiology , Renal Artery Obstruction/epidemiology , Adult , Age Factors , Amputation, Surgical , Aortic Aneurysm/surgery , Aortic Diseases/surgery , Carotid Stenosis/surgery , Cerebrovascular Disorders/surgery , Comorbidity , Constriction, Pathologic/epidemiology , Constriction, Pathologic/surgery , Disease Progression , Female , Heart Failure/epidemiology , Humans , Male , Middle Aged , Odds Ratio , Peripheral Vascular Diseases/surgery , Prevalence , Prognosis , Renal Artery Obstruction/surgery , Retrospective Studies , Vascular DiseasesABSTRACT
BACKGROUND: Endomyocardial biopsy (EMB) remains the gold standard for detecting acute rejection (AR) after heart transplantation (HTx). Non-invasive detection of AR thus far remains a challenge. Several studies have demonstrated that highly sensitive cardiac troponin T (hs-cTnT) concentrations have a low positive predictive value for diagnosing AR. Nevertheless, hs-cTnT proved to be useful for ruling out AR after HTx. An hs-cTnT concentration <17 ng/L, a value close to that used for rule-in or rule-out myocardial infarction, was associated with a 100% negative predictive value of AR. However, the cost-effectiveness of a strategy with the use of hs-cTnT for ruling out AR in HTx patients remains to be proven. METHODS: The cost-effectiveness of hs-cTnT determination for ruling out AR was assessed, comparing the costs of hs-cTnT measurements in 305 blood samples obtained at the time of EMB. Eighteen samples were excluded because the EMB was not assessable. RESULTS: Hs-cTnT determination cost 16.00 per sample, whereas EMB cost 1752.00 per biopsy; cost estimations included direct and indirect (30%) charges. Thirty-nine (13.6%) of the 287 blood samples presented hs-cTnT concentrations <17 ng/L; in none of them was an AR >2R degree found in the EMB. The cost of the assessment in the 287 blood samples and biopsies was of 4592.00 for hs-cTnT and 502,824.00 for EMB. Hs-cTnT systematic measurement would have avoided 39 EMB, with a saving of 68,328.00, which represents the 13.5% of the total budget expended in these cases. CONCLUSIONS: The use of hs-cTnT values to rule out the need of EMB for AR diagnosis after HTx appears to be a cost-effective procedure.
Subject(s)
Graft Rejection/blood , Heart Failure/surgery , Heart Transplantation , Myocardium/pathology , Troponin T/blood , Adult , Aged , Biomarkers/blood , Biopsy , Cost-Benefit Analysis , Female , Graft Rejection/diagnosis , Humans , Male , Middle AgedABSTRACT
BACKGROUND: Local fluid dynamics and exposed atherosclerotic lesions regulate thrombus formation. Activated cells in the attached thrombi release microparticles to the circulation (circulating microparticles [cMPs]); however, their phenotype is unknown. OBJECTIVES: To investigate the specific phenotype of the cMPs released by growing thrombi. METHODS/PATIENTS: cMPs released by thrombi growing in different well-characterized thrombogenic conditions were investigated. cMP contents just before and immediately after perfusion of the thrombogenic surfaces were analyzed by triple-labeling flow cytometry. cMPs were tested for their thrombin-generating capacity. The cMPs identified in the ex vivo perfusion experiments were validated in blood of ST-elevation myocardial infarction (STEMI) patients undergoing thrombectomy and percutaneous coronary intervention. Culprit coronary blood (STEMI-CCB) and peripheral artery blood (STEMI-PAB) were simultaneously analyzed and compared with peripheral artery blood from age-matched controls (C-PAB) and peripheral artery blood from patients who had recovered from acute coronary syndrome (ACS) (pSTEMI-PAB). RESULTS: The levels of annexin V(+) cMPs significantly increased in blood collected after perfusion of the exposed thrombogenic surfaces. cMP release was directly related to the formed thrombus mass and the plasma procoagulant activity. Post-thrombus blood showed higher thrombin generation potential and contained higher levels of cMPs carrying glycophorin-A (CD235a(+) ; erythrocyte-derived microparticles [ErMPs]) than preperfusion blood (P < 0.05), whereas the levels of cMPs carrying activated and adhesion platelet markers were decreased. STEMI-CCB and STEMI-PAB had significantly higher ErMP levels than control blood (P < 0.005). ErMP levels were also significantly higher in STEMI-PAB than in pSTEMI-PAB, validating the experimental mechanistic studies and suggesting that ErMPs are markers of ongoing coronary thrombosis (C-statistics: 0.950; 95% confidence interval 0.889-1.000; P < 0.001). CONCLUSION: Glycophorin-A-rich microparticles are released from evolving growing thrombi into the distal perfusing blood, and can be measured in peripheral blood. CD235a(+) cMPs may constitute a novel systemic biomarker of ongoing thrombosis.
Subject(s)
Blood Platelets/metabolism , Cell-Derived Microparticles/metabolism , Coronary Thrombosis/blood , Glycophorins/metabolism , Myocardial Infarction/blood , Platelet Activation , Aged , Biomarkers/blood , Case-Control Studies , Coronary Thrombosis/diagnosis , Coronary Thrombosis/therapy , Female , Flow Cytometry , Humans , Male , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/therapy , Percutaneous Coronary Intervention , Phenotype , Predictive Value of Tests , Reproducibility of Results , Thrombectomy , Thrombin/metabolism , Time Factors , Treatment OutcomeSubject(s)
Acute Coronary Syndrome/blood , Acute Coronary Syndrome/mortality , Natriuretic Peptide, Brain/blood , Stroke Volume/physiology , Acute Coronary Syndrome/physiopathology , Aged , Aged, 80 and over , Cohort Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis , Risk FactorsABSTRACT
BACKGROUND: The clinical outcomes of patients with fulminant acute myocarditis (FAM) range from death to complete recovery. We sought to identify clinical, biological, and echocardiographic characteristics of prognostic value for this population. METHODS AND RESULTS: We prospectively included 185 patients with the diagnosis of acute myocarditis who were admitted to our institution between 2000 and 2007, selecting 15 who displayed FAM, namely, severe congestive heart failure or cardiogenic shock, requiring inotropic and/or mechanical circulatory support. Their mean age was 27.9 +/- 12.4 years (range, 12-52) and mean left ventricular ejection fraction (LVEF) was 22 +/- 8.4% (range, 10-35). Seven subjects had poor outcomes, defined as death (n = 4), urgent transplantation (x = 2), or persistent left ventricular dysfunction (n = 3). The other 6 individuals experienced complete recovery of ventricular function. Troponin-I values below 1 ng/mL on admission were significantly associated with greater in-hospital (P = .05) and mid-term poor outcomes (P = .001). Additionally, patients with poor outcomes showed significantly lower LVEF (17.6 +/- 6.2% vs 28.8 +/- 6.9%; P = .006). CONCLUSION: Among patients with FAM, normal or minimal elevation of troponin-I and low LVEF on admission were associated with worse in-hospital and mid-term prognosis.
Subject(s)
Heart Transplantation/physiology , Myocarditis/blood , Troponin I/blood , Acute Disease , Adolescent , Adult , C-Reactive Protein/metabolism , Child , Female , Heart Failure/blood , Heart Failure/mortality , Heart Failure/surgery , Humans , Male , Middle Aged , Myocarditis/classification , Myocarditis/surgery , Prognosis , Severity of Illness Index , Shock, Cardiogenic/surgery , Treatment Outcome , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/surgery , Young AdultABSTRACT
BACKGROUND: There is a lack of consensus and insufficient data to assess the impact of late steroid withdrawal after heart transplantation (HTx). The aim of the study was to investigate the security and feasibility of corticosteroid withdrawal at 1 year after transplantation. METHODS AND RESULTS: Steroid withdrawal was attempted after at least 12 months of treatment in 86 HTx patients who fulfilled the criteria. At 1 and 3 months after drug discontinuation, patients underwent 2 endomyocardial biopsies (EMB). After a mean follow-up of 25 +/- 13 months, 63% of the patients remained steroid free. In 30 patients (35%) corticosteroids were reinitiated, in 15 cases because of acute rejection (7%), 5 (6%) because of worsening renal function, 5 (6%) because of malignancy, 3 (4%) because of adverse effects of immunosuppressive drugs, and 2 because of severe allograft coronary artery disease. Four patients (5%) died after drug discontinuation. There was a significant decrease in total cholesterol (198 +/- 35 to 181 +/- 38 mg/dL; P < .001) and low-density lipoprotain (LDL) cholesterol levels (113 +/- 30 to 105 +/- 30 mg/dL; P < .001). There were no differences in mortality between patients with and without corticosteroids. CONCLUSION: Steroid withdrawal is feasible and safe in HTx patients. In our study, it was successfully maintained in 63% of the patients. EMB is helpful to identify patients with acute rejection at 1 and 3 months after withdrawal. Short- to mid-term metabolic benefits are significant reductions in serum total and LDL cholesterol.
Subject(s)
Adrenal Cortex Hormones/therapeutic use , Heart Transplantation/physiology , Adrenal Cortex Hormones/adverse effects , Cholesterol/blood , Cholesterol, LDL/blood , Drug Administration Schedule , Feasibility Studies , Follow-Up Studies , Graft Rejection/drug therapy , Graft Rejection/epidemiology , Graft Rejection/immunology , Graft Rejection/mortality , Heart Transplantation/immunology , Heart Transplantation/mortality , Humans , Kidney Function Tests , Patient Selection , Reoperation/statistics & numerical data , Retrospective Studies , Substance Withdrawal Syndrome/physiopathology , Survival Rate , Time FactorsABSTRACT
BACKGROUND: Thrombospondin-1 (TSP-1) is a potent inhibitor of angiogenesis and an activator of tissue transforming growth factor-beta1 (TGF-beta1). Analyses using genetically modified mice suggested that TSP-1 may play a protective role to prevent infiltration and tissue remodeling responses after myocardial infarction. The expression levels of TSP-1 and their putative role in ventricular remodeling have not been determined in patients with heart failure (HF). MATERIALS AND METHODS: We analyzed the expression of TSP-1 and TGF-beta1 mRNA in myocardial biopsies from 34 subjects with end-stage HF undergoing heart transplantation and 13 healthy controls from heart donors. Among total RNA extracted from the left ventricle, 1 microg was retrotranscribed and mRNA expression levels were quantified by real-time polymerase chain reaction (PCR). RESULTS: The mean age of subjects was 54 +/- 2 years; mean ejection fraction, 21 +/- 5%; end-diastolic diameter and end-systolic diameter, 73 +/- 10 and 61 +/- 11 mm, respectively. TSP-1 mRNA expression in ventricular tissue from HF patients was lower (159.04 +/- 14.55 ng-equivalents [ng-equiv]) than in controls (234 +/- 30.66 ng-equiv; P < .05). Tissue from HF subjects also showed lower levels of TGF-beta1 (68.42 +/- 4.36 vs 80.58 +/- 5.26 ng-equiv; P < .05). TSP-1 mRNA levels correlated positively with TGF-beta1 (P = .001; R(2) = .2), and lower TSP-1 mRNA levels were observed with increasing left ventricular diameters. CONCLUSIONS: Patients with end-stage HF show decreased TSP-1 mRNA levels, which agrees with published results showing lower circulating TSP-1. Ventricular dilatation observed in these patients may be related to lower expression of TSP-1. Surprisingly, TGF-beta1 mRNA levels were lower in failing hearts, which suggested that fibrogenesis takes place in earlier phases of HF.
Subject(s)
Heart Failure/genetics , Heart Transplantation/pathology , Thrombospondin 1/genetics , Ventricular Remodeling/genetics , Biopsy , Female , Gene Expression Regulation , Heart Failure/pathology , Humans , Male , Middle Aged , Polymerase Chain Reaction , RNA/genetics , RNA, Messenger/genetics , Reference Values , Spectrophotometry , Tissue Donors , Transcription, Genetic , Transforming Growth Factor beta1/geneticsABSTRACT
BACKGROUND: The aim of the present research was to study the possible interference of hemosiderin deposits with the histological detection of dextran-coated, iron-labeled, mesenchymal stem cells after intracoronary administration in a porcine model of myocardial infarction. MATERIALS AND METHODS: A myocardial infarction was induced in six animals that received intracoronary iron-labeled autologous mesenchymal stem cells (group 1; n = 2) or placebo (group 2; n = 4). Six control animals without myocardial infarction underwent direct intramyocardial injections of iron-labeled autologous mesenchymal stem cells (group 3; n = 2) or placebo (group 4; n = 4). Histological sections from explanted hearts were stained with Prussian blue to identify dextran-coated, iron-labeled, mesenchymal stem cells. RESULTS: After Prussian blue staining, granular blue labeling in the tissue was observed in both groups of animals with infarcts. Similar granular blue labeling was detected in hearts from control animals without infarction that had received iron-labeled mesenchymal stem cells. However, hearts from control animals without infarction that received placebo did not have any granular blue labeling in the tissue. CONCLUSIONS: Hemosiderin from infarction hemorrhage interferes with detection of dextran-coated iron-labeled mesenchymal stem cells after intracoronary administration, suggesting that this marker is not useful to detect mesenchymal stem cells in a porcine model of myocardial infarction.
Subject(s)
Ferric Compounds , Hemosiderin/analysis , Mesenchymal Stem Cells/cytology , Myocardial Infarction/pathology , Stem Cell Transplantation/methods , Animals , Cell Separation/methods , Disease Models, Animal , Ferric Compounds/analysis , Myocardial Infarction/surgery , Swine , Transplantation, AutologousABSTRACT
The amniotic fluid embolism is an uncommon condition with a high mortality. The cardinal symptoms are hypoxia, hypotension, altered mental status and disseminated intravascular coagulation. This syndrome occurs during delivery or in the immediate postpartum period, and its onset in the late postpartum is very unusual. We describe a case of a primigravida who, after an uneventful delivery, suffers an acute respiratory failure in the late postpartum period. Exclusion of other causes of acute respiratory failure occurring during delivery or in the postpartum period led to establish the diagnosis.
Subject(s)
Amniotic Fluid , Embolism/complications , Puerperal Disorders/diagnosis , Respiratory Insufficiency/diagnosis , Acute Disease , Adult , Diagnosis, Differential , Female , Humans , Respiratory Insufficiency/etiologyABSTRACT
La embolia de líquido amniótico es un síndrome poco frecuente, y a menudo fatal, cuyas principales manifestaciones clínicas son la hipoxia, la hipotensión, la alteración del estado de consciencia y la coagulación intravascular diseminada. Tiene lugar durante el parto o en el posparto inmediato, siendo excepcional su aparición en el posparto tardío. Presentamos el caso de una primigrávida que tras un parto sin complicaciones desarrolla un cuadro de insuficiencia respiratoria aguda en el posparto tardío. La exclusión de otras causas de insuficiencia respiratoria aguda durante el parto y posparto permitió establecer el diagnóstico
The amniotic fluid embolism is an uncommoncondition with a high mortality. The cardinalsymptoms are hypoxia, hypotension, alteredmental status and disseminated intravascular coagulation.This syndrome occurs during deliveryor in the immediate postpartum period, and its onsetin the late postpartum is very unusual. We describea case of a primigravida who, after an uneventfuldelivery, suffers an acute respiratory failurein the late postpartum period. Exclusion ofother causes of acute respiratory failure occurringduring delivery or in the postpartum periodled to establish the diagnosis (AU)
Subject(s)
Humans , Female , Pregnancy , Embolism, Amniotic Fluid/diagnosis , Respiratory Insufficiency/diagnosis , Diagnosis, Differential , Hypotension/etiology , Cardiomyopathies/complications , Puerperal DisordersABSTRACT
Due to the strong relationship between abdominal aortic aneurysm (AAA) and coronary morbidity and mortality, it seems mandatory to spend some more time investigating about coronary risk of our endovascular aortic repair (EVAR) patients. Physical examination, basic laboratory testing and ECG will allow us to determine whether the surgical risk for a patient is low, moderate or high. In general a patient who is at low risk will not need any further evaluation. Those at who are at high risk usually will undergo coronary angiography. Patients who are at intermediate risk, probably the largest subgroup of patients candidate to EVAR, will often need additional testing like assessment of resting left ventricular function, exercise stress testing, pharmacological stress testing, ambulatory ECG monitoring, and coronary angiography as well as exercise echocardiography or exercise myocardial perfusion imaging should be considered. Patients undergoing an EVAR procedure, who are found to have prognostic high-risk coronary anatomy and in whom long-term outcome would likely be improved by coronary revascularization, should generally undergo revascularization first. In conclusion, we recommend to evaluate the cardiac status of EVAR's patients in order to reduce the most common serious morbidity related to this new therapeutic modality.